Virax Biolabs Group annual depreciation and amortization
2022
2023
2024
2025
2026
Virax Biolabs Group Depreciation & Amortization Growth & History (VRAX)
Virax Biolabs Group's depreciation and amortization was $439,018 for fiscal 2026.
View full Virax Biolabs Group company overviewVirax Biolabs Group annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $439,018 | $172,417 | +64.67% |
| 2025 | 2025-03-31 | $266,601 | $211,731 | +385.88% |
| 2024 | 2024-03-31 | $54,870 | $54,870 | — |
| 2023 | 2023-03-31 | $0 | $0 | — |
| 2022 | 2022-03-31 | $0 | — | — |
Virax Biolabs Group depreciation and amortization trends
Between the periods ended 2022-03-31 and 2026-03-31, Virax Biolabs Group's depreciation and amortization increased from $0 to $439,018, a change of $439,018.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Virax Biolabs Group source filings ↗